Summary & Overview
CPT 96413: Chemotherapy Administration, Intravenous Infusion Up to One Hour
CPT 96413: Chemotherapy Administration, Intravenous Infusion Up to One Hour
CPT code 96413 is a critical billing code in oncology, representing the administration of chemotherapy through intravenous infusion for up to one hour, covering a single or initial substance or drug. This procedure is a cornerstone of cancer treatment, performed in outpatient hospital infusion centers and physician offices nationwide. The code is widely recognized by major payers, including Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare, ensuring broad coverage for patients undergoing chemotherapy.
This publication provides a comprehensive overview of CPT 96413, detailing its clinical context, typical sites of service, and its role in the broader landscape of oncology billing. Readers will gain insight into payer coverage, relevant policy updates, and benchmarks for chemotherapy infusion services. The article also highlights related codes and modifiers that distinguish subsequent doses and additional hours of infusion, supporting accurate billing and compliance. With a focus on national standards, the summary equips healthcare professionals, administrators, and policy analysts with essential information to understand the significance and application of CPT 96413 in cancer care.
CPT Code Overview
CPT 96413 is used to report the administration of chemotherapy via intravenous infusion for up to one hour, covering a single or initial substance or drug. This code is central to oncology and infusion medicine, reflecting a common procedure in cancer treatment protocols. Typical sites of service include outpatient hospital infusion centers (such as Place of Service 22) and physician offices (Place of Service 11), where patients receive chemotherapy under medical supervision. The code is essential for accurately documenting and billing the initial hour of intravenous chemotherapy infusion, ensuring proper tracking of clinical services provided in these settings.
Clinical & Coding Specifications
Clinical Context
A patient diagnosed with a malignant neoplasm, such as breast, lung, colon, prostate, or pancreatic cancer, presents to an outpatient hospital infusion center or oncology office for chemotherapy treatment. The provider reviews the patient's medical history and confirms the chemotherapy regimen. The initial intravenous infusion of a single chemotherapy drug is started and monitored for up to one hour. The clinical workflow includes pre-infusion assessment, preparation of the drug, initiation of the IV infusion, monitoring for adverse reactions, and post-infusion documentation. This scenario is typical for patients undergoing scheduled chemotherapy as part of their cancer management plan.
Coding Specifications
- Modifier
EJ: Used to indicate a subsequent dose in a series of the same drug. Do not report an initial dose with theEJmodifier.
| Modifier Code | Description |
|---|---|
EJ | Subsequent Dose in a Series; used to distinguish subsequent doses of the same drug in a sequential series—do not report an initial dose with the EJ modifier. |
- Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
207P00000X | Internal Medicine, Oncology |
- Specialties Represented:
- Internal Medicine
- Oncology
Related Diagnoses
-
C50.911: Malignant neoplasm of unspecified site of right female breast- Relevant for patients receiving chemotherapy for breast cancer.
-
C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung- Relevant for patients undergoing chemotherapy for lung cancer.
-
C18.9: Malignant neoplasm of colon, unspecified- Relevant for patients receiving chemotherapy for colon cancer.
-
C61: Malignant neoplasm of prostate- Relevant for patients undergoing chemotherapy for prostate cancer.
-
C25.9: Malignant neoplasm of pancreas, unspecified- Relevant for patients receiving chemotherapy for pancreatic cancer.
Each diagnosis code represents a type of cancer for which intravenous chemotherapy administration (96413) is clinically indicated.
Related CPT Codes
| CPT Code | Description | Clinical Relationship |
|---|---|---|
96415 | Chemotherapy administration, intravenous infusion technique; each additional hour (beyond the initial hour) of a single or initial substance/drug. | Used when the infusion exceeds one hour; reported in addition to 96413. |
96417 | Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (initial code is 96413). | Used for additional sequential infusions after the initial infusion. |
96360 | Intravenous infusion, hydration; initial, up to one hour (supportive hydration therapy not separately reportable if concurrent). | Used for hydration therapy; not separately reportable if performed concurrently with chemotherapy. |
96361 | Intravenous infusion, hydration; each additional hour (used when hydration is secondary or subsequent to another infusion). | Used for additional hours of hydration following another infusion. |
96366 | Therapeutic, prophylactic or diagnostic nonchemotherapy drug infusion; additional sequential infusion. | Used for nonchemotherapy drug infusions administered sequentially. |
96367 | Therapeutic, prophylactic or diagnostic nonchemotherapy drug infusion; each additional hour. | Used for additional hours of nonchemotherapy drug infusion. |
96375 | Therapeutic, prophylactic or diagnostic nonchemotherapy drug injection; initial, single or initial substance/drug. | Used for initial injection of nonchemotherapy drugs. |
96376 | Therapeutic, prophylactic or diagnostic nonchemotherapy drug injection; each additional sequential injection. | Used for additional sequential injections of nonchemotherapy drugs. |
96411 | Chemotherapy administration, intravenous infusion technique; IV push administration of additional drugs/substances at the same session. | Used for IV push administration of additional chemotherapy drugs during the same session as 96413. |
- Codes
96415and96417are commonly used together with96413when the infusion duration or number of drugs increases. - Codes
96360,96361,96366,96367,96375, and96376are alternatives or adjuncts for nonchemotherapy infusions or injections during the same visit.
National Reimbursement Benchmarks
National mean rates for CPT code 96413 show a significant gap between Medicare and commercial payers. Medicare's mean rate is $139.17, while the BUCA (average commercial) mean rate stands at $199.06, highlighting a difference of nearly $60 per claim.
Rate dispersion varies notably across payers. Medicare exhibits the tightest range, with a difference of $18.00 between its 75th and 25th percentiles. In contrast, Cigna has the widest spread, with a $123.00 difference between its 75th and 25th percentiles, indicating greater variability in commercial reimbursement. Blue Cross Blue Shield, Aetna, and UnitedHealth Group also show broader ranges compared to Medicare.
The table and chart below present the full breakdown of national benchmarks for each payer, including mean rates and percentile values.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.